Is sleeve gastrectomy a therapeutic procedure for all obese patients?
Our experience indicates that LSG is a safe procedure with satisfactory three-year late weight loss in patients with preoperative BMI<50 kg/m2. Promising results, in terms of improvements of comorbidities, were also observed. These results make LSG one of the most attractive first stage surgical procedure for morbid obesity.
Individuals with chronic kidney disease benefit from combination cardioprotective therapy, but are less likely to be prescribed them after acute myocardial infarction. Further investigation is warranted to identify possible reasons for these observed treatment disparities.